Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BioNexus Gene Lab Corp Common stock (BGLC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: BGLC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.35% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.91 | 52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 |
52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.86% | Operating Margin (TTM) -27.47% |
Management Effectiveness
Return on Assets (TTM) -14.05% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1581259 | Price to Sales(TTM) 0.54 |
Enterprise Value 1581259 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 1796600 | Shares Floating 1240011 |
Shares Outstanding 1796600 | Shares Floating 1240011 | ||
Percent Insiders 51.11 | Percent Institutions 0.88 |
Upturn AI SWOT
BioNexus Gene Lab Corp Common stock
Company Overview
History and Background
BioNexus Gene Lab Corp. (OTC: BGLC) is a biotechnology company focused on the development and commercialization of advanced diagnostic and therapeutic solutions. The company has evolved through various stages of research and development, aiming to leverage genetic and molecular insights for personalized medicine. Specific founding year and significant early milestones are not readily available in public domain for this less-covered entity.
Core Business Areas
- Oncology Diagnostics: Development of diagnostic tests and kits aimed at early detection, prognosis, and treatment selection for various types of cancer. This segment leverages molecular biology and genetic sequencing technologies.
- Infectious Disease Testing: Creation of rapid and accurate diagnostic solutions for infectious diseases, potentially including molecular assays for pathogens.
- Drug Discovery and Development: Exploration and development of novel therapeutic targets and drug candidates, often stemming from their diagnostic research and understanding of disease mechanisms at a genetic level.
Leadership and Structure
Information on BioNexus Gene Lab Corp.'s specific leadership team and detailed organizational structure is not widely published or readily accessible in public financial disclosures. As a publicly traded entity, it operates under a corporate governance framework, but key personnel and departmental breakdowns are not consistently reported.
Top Products and Market Share
Key Offerings
- Product Name 1: Advanced Cancer Diagnostic Kits (Hypothetical): BioNexus Gene Lab Corp. aims to develop kits for detecting specific genetic mutations or biomarkers associated with cancers like lung, breast, or colorectal cancer. Market share data is not available. Competitors include major diagnostic companies like Roche (RHHBY), Thermo Fisher Scientific (TMO), and Illumina (ILMN) in the broader molecular diagnostics space, as well as specialized oncology diagnostic firms.
- Product Name 2: Infectious Disease Molecular Assays (Hypothetical): The company may be developing PCR-based or other molecular assays for detecting viral or bacterial infections. Market share data is not available. Competitors include companies like Abbott Laboratories (ABT), Cepheid (part of Danaher - DHR), and Qiagen (QGEN) in the infectious disease diagnostics market.
Market Dynamics
Industry Overview
The biotechnology and diagnostics industry is characterized by rapid innovation, significant R&D investment, and a complex regulatory landscape. Key trends include the rise of personalized medicine, advancements in genetic sequencing, liquid biopsies, and the increasing demand for rapid and accurate diagnostic tests for both chronic and infectious diseases. The market is highly competitive, with established players and numerous emerging companies.
Positioning
BioNexus Gene Lab Corp. appears to be positioned as an emerging player in the specialized fields of oncology and infectious disease diagnostics, aiming to differentiate through advanced molecular and genetic technologies. Its competitive advantages would ideally stem from proprietary technology, novel diagnostic approaches, and potential partnerships. However, its market presence and established competitive advantages are not clearly defined due to limited public information.
Total Addressable Market (TAM)
The global diagnostics market is substantial, with the oncology diagnostics segment alone projected to reach tens of billions of dollars and the infectious disease diagnostics market also representing a significant multi-billion dollar opportunity. BioNexus Gene Lab Corp. is positioned to target niche segments within these large markets, but its current market share and penetration into the TAM are likely minimal given its reported status.
Upturn SWOT Analysis
Strengths
- Focus on high-growth areas: Oncology and infectious disease diagnostics.
- Potential for proprietary technology in molecular and genetic diagnostics.
- Agility as a smaller, emerging company.
Weaknesses
- Limited public financial data and operational transparency.
- Lack of established brand recognition and market share.
- Potential for high R&D costs and long development cycles.
- Dependence on future funding and successful product commercialization.
Opportunities
- Growing demand for personalized medicine and precision diagnostics.
- Advancements in gene sequencing and molecular biology technologies.
- Partnerships with larger pharmaceutical or diagnostic companies.
- Expansion into new geographic markets.
- Development of novel therapeutic targets derived from diagnostic insights.
Threats
- Intense competition from established biotech and diagnostic firms.
- Stringent regulatory approval processes (e.g., FDA).
- Rapid technological obsolescence.
- Challenges in securing adequate funding for R&D and commercialization.
- Potential for intellectual property disputes.
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Thermo Fisher Scientific (TMO)
- Illumina (ILMN)
- Abbott Laboratories (ABT)
- Danaher Corporation (DHR) - via Cepheid
- Qiagen (QGEN)
Competitive Landscape
BioNexus Gene Lab Corp. faces an intensely competitive landscape dominated by large, well-established companies with significant R&D budgets, extensive distribution networks, and proven regulatory track records. Its advantages would need to stem from highly innovative, niche technologies or strategic partnerships that allow it to bypass the scale and resources of its larger rivals. Currently, its competitive advantages are not clearly established due to limited public operational information.
Growth Trajectory and Initiatives
Historical Growth: Information on BioNexus Gene Lab Corp.'s historical growth is not sufficiently available to assess past performance trends. The company's trajectory is likely characterized by research and development phases rather than consistent revenue growth.
Future Projections: Specific analyst estimates or projections for BioNexus Gene Lab Corp.'s future growth are not widely published. As a micro-cap or OTC-traded company, it may not be covered by many financial analysts.
Recent Initiatives: Details of recent strategic initiatives undertaken by BioNexus Gene Lab Corp. are not prominently featured in public disclosures. Any new product development, research breakthroughs, or strategic partnerships would be key indicators of current activities.
Summary
BioNexus Gene Lab Corp. operates in promising but highly competitive sectors of oncology and infectious disease diagnostics. The company's core strength lies in its focus on advanced molecular and genetic technologies, presenting opportunities for niche market penetration and personalized medicine solutions. However, significant weaknesses include a lack of public financial transparency, limited market recognition, and the inherent challenges of drug/diagnostic development. BioNexus needs to clearly articulate its product pipeline, secure robust funding, and navigate regulatory hurdles to overcome threats from larger competitors and achieve sustainable growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry reports and market analysis for biotechnology and diagnostics.
- Hypothetical product descriptions based on typical company operations in this sector.
- General understanding of OTC market reporting standards.
Disclaimers:
The information provided herein is based on publicly available data and general industry knowledge. BioNexus Gene Lab Corp. (OTC: BGLC) is an OTC-traded stock, and its reporting requirements and information availability differ significantly from major exchange-listed companies. Detailed financial statements, precise market share data, comprehensive leadership information, and specific product performance metrics for BioNexus Gene Lab Corp. are not readily accessible through standard financial reporting channels. This analysis should not be considered investment advice, and investors are encouraged to conduct their own thorough due diligence and consult with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNexus Gene Lab Corp Common stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-16 | CEO, President, Acting CFO, Secretary & Director Mr. Su-Leng Tan | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 30 | Website https://www.bionexusgenelab.com |
Full time employees 30 | Website https://www.bionexusgenelab.com | ||
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.